Compare · ILMN vs YDES
ILMN vs YDES
Side-by-side comparison of Illumina Inc. (ILMN) and YD Bio Limited (YDES): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ILMN and YDES operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $19.43B, about 50.5x YDES ($385.0M).
- Over the past year, ILMN is up 65.7% and YDES is down 60.7% - ILMN leads by 126.4 points.
- ILMN has been more active in the news (5 items in the past 4 weeks vs 1 for YDES).
- ILMN has more recent analyst coverage (25 ratings vs 0 for YDES).
- Company
- Illumina Inc.
- YD Bio Limited
- Price
- $127.93+2.01%
- $5.25+4.79%
- Market cap
- $19.43B
- $385.0M
- 1M return
- +1.37%
- -33.59%
- 1Y return
- +65.69%
- -60.70%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- News (4w)
- 5
- 1
- Recent ratings
- 25
- 0
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest ILMN
- DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows
- Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease
- Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026
- SEC Form DEFA14A filed by Illumina Inc.
- SEC Form DEF 14A filed by Illumina Inc.
- SEC Form 4 filed by Ullem Scott B.
- SEC Form 4 filed by Meister Keith A.
- Illumina Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Illumina Announces Changes to Board of Directors
- Amendment: SEC Form SCHEDULE 13G/A filed by Illumina Inc.
Latest YDES
- Amendment: SEC Form 3 filed by new insider Lu Shao-Ta
- SEC Form 4 filed by Lu Shao-Ta
- SEC Form 4 filed by Chang Kochi
- SEC Form 3 filed by new insider Lu Shao-Ta
- SEC Form 3 filed by new insider Chang Kochi
- YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States
- SEC Form 3 filed by new insider Lee Jerry Yin-Chia
- SEC Form 3 filed by new insider Zhang Bo-Xiang
- SEC Form 3 filed by new insider Hen Man Edmund
- SEC Form 3 filed by new insider Shen Ethan Phd